

Index

- abnormal brain scan
 adult onset polyglucosan body disease, 76–8
 Alzheimers disease with MS and, 50–2
 CADASIL, 56–7
 fragile X associated tremor ataxia syndrome (FXTAS), 67–8
 Moyamoya syndrome, 60
 multiple systems atrophy cerebellar type (MSA-C), 68
 optic atrophy, 41
 optic nerve edema and headache, 44–5
 static cervical myelopathy, 79–80
 three-step assessments, 8–9, 12–13
- acquired autoimmune acute cerebellitis, 66–7
- acute hemorrhagic leukoencephalitis, 73–4
- acute inflammatory demyelinating polyneuropathy (AIDP), 12
 paroxysmal tonic spasms with, 23
- acute myelopathy, 1–4
- adult onset polyglucosan body disease, 76–8
- Alexander disease, 72–3
- alien limb phenomenon
 gliomatosis cerebri, 52–4
 progressive white matter disease, 54–6
- Alzheimers disease, multiple sclerosis and, 50–2
- anticoagulation therapy, superficial siderosis, 72
- antiepileptic drugs, tonic spasm management, 23
- antinuclear antibody (ANA), neuromyelitis optica (NMO) spectrum disease, 75–6
- arteriovenous malformation, spinal cord, 87–8
- Ashkenazi Jewish population, adult onset polyglucosan body disease, 76–8
- ataxia, 1–4. *See* gait impairment
 acquired autoimmune acute cerebellitis, 66–7
 Alexander disease, 72–3
- cervical myelopathy, 85–6
 CLIPPERS syndrome, 74–5
 fragile X associated tremor ataxia syndrome, 67–8
 lymphoma and Sjögren syndrome, 68–9
 MS diagnosis, 3–4
 multiple systems atrophy cerebellar type (MSA-C), 68
 NMDA receptor antibody encephalitis/ovarian teratoma, 58–60
 paroxysmal symptoms, 25–6
 progressive cerebellar, 64–5
- autosomal-dominant leukodystrophy, 61–2
- avascular hip necrosis, MS patients with lower extremity pain, 37–9
- B12 deficiency, cervical myelopathy with, 1
- Babinski signs, MS diagnosis, 3–4
- benign MS, pregnant patients, management of, 35
- benign relapsing remitting multiple sclerosis, clinical course assessment, 17
- binocular vision loss
 clinically isolated syndrome, 21–2
 lower extremity weakness and, 27–8
 MS diagnosis and, 1–4
 relapsing remitting MS, 31–3
 “black hole lesions,” T1-weighted imaging
 investigational evidence, MS diagnosis, 4–6
 reduction of, 30
- bladder dysfunction. *See also* incontinence
 adult onset polyglucosan body disease, 76–8
 MS diagnosis, 1
 MS differential diagnosis and, 13–14
- bowel dysfunction, MS diagnosis, 1
- brain demyelinating lesions, headache and, 16
- brainstem auditory evoked potentials (BAEP)
 MS diagnosis, 5–6
 sensorineural deafness, 12–13
- brainstem demyelination
 acute hemorrhagic leukoencephalitis, 73–4
 CLIPPERS syndrome, 74–5
 diagnostic challenges, 71–8
 relapsing remitting MS, 71–2
- breast cancer, obstructive hydrocephalus/corpus callosum abnormalities, 57–8
- breastfeeding, therapeutic management of MS and, 35
- carpal tunnel syndrome, three-step assessment case study, 11–12
- central nervous system (CNS) demyelination
 corpus callosal abnormalities, 57–8
 McArdle’s sign, 27–8
 MS differential diagnosis, 1–4
 radiologically isolated syndrome, 15–16
 repetitive limb spasms, 23
- cerebellar demyelination
 acquired autoimmune acute cerebellitis, 66–7
 diagnostic pitfalls, 64–70
 dysarthria, MS diagnosis, 3–4
 progressive ataxia and isolated lesions, 64–5
 progressive tremor, 64
- cerebellar pilocytic astrocytoma, 64–5
- cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), 56–7
- cerebral parenchymal disease. *See also* cognitive impairment; dementia
 diagnostic pitfalls, 50–62
- cerebrospinal fluid (CSF) examination
 MS diagnosis, 5–6
 sensorineural deafness, 12–13
- cervical fusion, gait impairment, 80
- cervical myelopathy
 CADASIL, 56–7
 copper deficiency, 85–6
 differential diagnosis, 79–80
 gait impairment, 82–3
 ischemic thoracic myelopathy, 83–4
 left-sided pain/inflammatory myelopathy, 84–5

Index

- MS differential diagnosis and, 1, 9–11
- primary progressive multiple sclerosis, 81
- spinal cord herniation, 86–7
- chronic cerebrospinal venous insufficiency (CCSVI), therapy for MS patients with, 36
- chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS), 74–5
- classical clinical features of MS, overview of, 1–4
- clinical course assessment
- overview of, 15–16
 - radiologically isolated syndrome (RIS), 16
- clinically isolated syndrome (CIS)
- clinical course assessment, 15–16
 - risk of MS and, 21–2
 - three-step assessment case study, 9–11
- cognitive impairment
- Alzheimers with MS, 50–2
 - multiple sclerosis, 50
- complex regional pain syndrome, MS differential diagnosis, 8–9
- compressive cervical spondylotic myelopathy, MS differential diagnosis and, 1
- copper deficiency myeloneuropathy, 85–6
- corpus callosum abnormalities, breast cancer and, 57–8
- corticospinal tract impairment, MS diagnosis, 3–4
- deafness, MS differential diagnosis, 12–13
- dementia, multiple sclerosis and, 50
- demyelinating cerebellar disease, diagnostic pitfalls, 64–70
- demyelinating ocular disease, diagnostic challenges, 40–8
- diffuse pain, MS diagnosis and, 8–9
- dimethyl fumarate, psoriasis in MS patients and, 35–6
- diplopia, 1–4
- benign relapsing remitting multiple sclerosis, 17
 - clinically isolated syndrome, 21–2
 - lower extremity weakness and, 27–8
 - relapsing remitting MS, 71–2
- distal vibratory sensory loss, MS diagnosis, 2–3
- dorsal spinal cord dysfunction, MS diagnosis, 3–4
- dysarthria, 1–4, 8
- acquired autoimmune acute cerebellitis, 66–7
 - Moyamoya syndrome, 60
 - paroxysmal symptoms, 25–6
 - relapsing remitting MS, 71–2
- dysconjugate nystagmus, MS diagnosis, 3–4
- dyskinesias, NMDA receptor antibody encephalitis and, 58–60
- electrophysiological examination, MS diagnosis, 5–6
- ephaptic transmission (cross talk), paroxysmal symptoms of ataxia/dysarthria, 25–6
- exertion, lower extremity weakness following, 27–8
- facial pain, visual loss and, 48
- facial tingling, CLIPPERS syndrome, 74–5
- fatigue, benign relapsing remitting MS, 17
- fibromyalgia, migraine and, 8–9
- fragile X associated tremor ataxia syndrome (FXTAS), 67–8
- gadolinium-enhancing lesions, 4–8
- clinically isolated syndrome, 15–16
 - relapsing remitting multiple sclerosis, 31–3
 - treatment-resistant MS, tobacco use and, 30–1
- gait impairment. *See also* ataxia
- acquired autoimmune acute cerebellitis, 66–7
 - adult onset polyglucosan body disease, 76–8
 - autosomal-dominant leukodystrophy, 61–2
 - cervical fusion surgery and, 80
 - cervical myelopathy, 82–3, 85–6
 - clinical course assessment, 19–21
 - fragile X associated tremor ataxia syndrome (FXTAS), 67–8
 - MS diagnosis, 1
 - multiple systems atrophy cerebellar type (MSA-C), 68
 - Parkinson's disease diagnosis, 13–14
 - pseudo exacerbations, 18–19
 - relapsing remitting MS, 33
 - superficial siderosis, 72
 - therapeutic management of MS and, 33–4
 - visual impairment and, 28–9
- glatiramer acetate
- psoriasis in MS patients and incomplete response to, 35–6
 - unresponsiveness to, 31–3
- glial fibrillary acidic protein (GFAP), Alexander disease, 72–3
- gliomatosis cerebri, 52–4
- “glove” distribution of sensory loss, clinically isolated syndrome (CIS), 10
- granular osmiophilic material (GOM), CADASIL, 56–7
- Guillan-Barre syndrome, 12
- headache
- brain demyelinating lesions, 16
 - clinically isolated syndrome, 21–2
 - optic nerve edema and, 44–5
- hemiparesis, 1–4
- gliomatosis cerebri, 52–4
- Moyamoya syndrome, 60
- primary progressive multiple sclerosis, 81
- hemisensory loss, 1–4
- heralding symptoms of MS, trigeminal neuralgia, 24–5
- herniation, spinal cord, 86–7
- “hot cross bun” sign, multiple systems atrophy cerebellar type (MSA-C), 68
- Hurst disease. *See* acute hemorrhagic leukoencephalitis
- hypothalamic involvement, longstanding MS, 26–7
- hypothermia, recurrent encephalopathy, 26–7
- idiopathic intracranial hypertension, 42–3
- immunoglobulin G (IgG) index
- acquired autoimmune acute cerebellitis, 66–7
 - cerebrospinal fluid (CSF) examination, 5–6
 - relapsing remitting MS, 71–2
- immunomodulation therapy, relapsing remitting multiple sclerosis, 30–1
- immunosuppressive therapies, neuromyelitis optica (NMO) spectrum disease, 43–4
- incontinence
- autosomal-dominant leukodystrophy, 61–2
 - multiple systems atrophy cerebellar type (MSA-C), 68
- inflammatory MS phenotypes
- clinical course assessment, 15–16
 - glatiramer acetate unresponsiveness and, 31–3
 - MRI analysis, 30
- injection intolerance, relapsing remitting MS and, 33

Index

- interferon therapy
MS management with, 33–4
psoriasis in MS patients and, 35–6
internuclear ophthalmoplegia (INO)
MS diagnosis, 3–4
relapsing remitting multiple sclerosis, 40
investigational evidence assessment,
MS diagnosis, 4–6
ischemic myelopathy, 83–4
- JC virus antibody
MALT lymphoma and Sjögren
syndrome, 68–9
relapsing remitting multiple
sclerosis, 30–1
therapeutic management of MS and
assessment of, 33–4
- Kokmen short test of mental status,
50–2
CADASIL, 56–7
fragile X associated tremor ataxia
syndrome, 67–8
progressive white matter disease,
54–6
- Lamin B1 (LMNB1) gene, autosomal-
dominant leukodystrophy, 61–2
Leber's hereditary optic neuropathy
(LHON), 48
Lhermitte symptoms, 1–4
benign relapsing remitting multiple
sclerosis, 17
psoriasis in MS patients and, 35–6
relapsing remitting multiple
sclerosis, 31–3
treatment-resistant MS, tobacco use
and, 30–1
- lower extremity weakness
pain in MS patients with, 37–9
as paroxysmal symptom, 27–8
spinal cord arteriovenous
malformation, 87–8
- magnetic resonance imaging (MRI)
abnormal brain scan, 8–9, 12–13
gait impairment, clinical course
assessment, 19–21
investigational evidence, MS
diagnosis, 4–6
malignant hypertension, optic
neuropathy with, 44–5
MALT lymphoma, 68–9
McArdle's sign, secondary progressive
MS, 27–8
memory loss, Alzheimers disease with
MS and, 50–2
migraine headaches
MS differential diagnosis, 8–9
- three-step assessment case study,
non-specific findings, 8
MS mimickers, investigations of, 6–8
multiple sclerosis (MS)
defined, 1
three-step diagnosis, 1–6
multiple systems atrophy cerebellar
type (MSA-C), 68
mutism, NMDA receptor antibody
encephalitis/ovarian teratoma,
58–60
- natalizumab, MS management with,
33–4
neck flexion, lower extremity weakness
and, 27–8
neurological examination
assessment of improvement, 30
MS diagnosis, 3–4
primary progressive multiple
sclerosis, 13–14
neuromyelitis optica (NMO) spectrum
disease, 43–4
intractable vomiting, 75–6
neuron-specific enolase (NSE), 50
neuroradiological testing, MS
diagnosis, 5–6
neuroretinitis, 46
neurosarcoidosis, optic nerve
neuropathy and, 47–8
NMDA receptor antibody encephalitis,
psychiatric symptoms, 58–60
numbness. *See* sensory loss
- obstructive hydrocephalus, breast
cancer and, 57–8
oligoclonal bands
Alzheimers disease with MS and,
50–2
cerebrospinal fluid (CSF)
examination, 5–6
cognitive impairment with MS and,
50
relapsing remitting MS, 71–2
sensorineural deafness, 12–13
optic atrophy, 41
optic nerve edema, 44–5
chest abnormality with, 47–8
recurrent visual loss, 46
optic neuritis, 1–4
differential diagnosis, 42–3
neuromyelitis optica spectrum
disease with, 43–4
optic neuropathy. *See also* Leber's
heredity optic neuropathy
(LHON)
malignant hypertension with
leukoencephalopathy, 44–5
neurological examination, 3–4
neurosarcoidosis and, 47–8
- oral MS therapy, psoriasis in MS
patients and, 35–6
orofacial movements (involuntary),
NMDA receptor antibody
encephalitis/ovarian teratoma,
58–60
ovarian teratoma, NMDA receptor
antibody encephalitis with, 58–60
- pain management, in MS patients,
assessment of, 37–9
papilledema, differential diagnosis, 42–3
papillitis. *See* optic neuritis
paraparesis, 1–4
parasthesias, MS differential diagnosis,
11–12
Parkinson's disease, MS differential
diagnosis and, 13–14
paroxysmal symptoms of MS, 23–9
ataxia and dysarthria, 25–6
repetitive limb spasms, 23
Uhthoff phenomenon, 28–9
peripheral nerve disease
cervical myelopathy, 85–6
three-step assessment case study,
11–12
Phalen's test, 11–12
postvaccinal inflammatory thoracic
myelitis, 84–5
pregnancy, in MS patients, 35
primary progressive multiple sclerosis
gait impairment, 80
Parkinson's disease, differential
diagnosis, 13–14
solitary sclerosis presentation, 81
primary progressive multiple sclerosis
(PPMS), clinical course
assessment, 15–16
progressive, neurodegenerative MS,
clinical course assessment, 15–16
progressive multifocal
leukoencephalopathy (PML), 30
cerebellar granule cells, 68–9
optic neuropathy with hypertension,
44–5
white matter disease and alien limb,
54–6
progressive myelopathy, 1–4
pseudo exacerbations
secondary progressive MS, 18–19
therapeutic management of MS and,
34–5
pseudotumor cerebri, 42–3
psoriasis, therapeutic management in
MS patients, 35–6
psychiatric symptoms
Alexander disease, 72–3
NMDA receptor antibody
encephalitis/ovarian teratoma,
58–60

- quadripareisis, 1–4
- radiologically isolated syndrome (RIS)
 - clinical course assessment, 15–16
- recurrent encephalopathy,
 - hypothermia with, 26–7
- relapsing remitting multiple sclerosis (RRMS)
 - benign form, 17
 - clinical course assessment, 15–16
 - clinically isolated syndrome and risk for, 21–2
 - differential diagnosis, 16
 - glatiramer acetate unresponsiveness, 31–3
 - injection intolerance, 33
 - internuclear ophthalmoplegia, 40
 - nicotine dependence and, 30–1
 - psoriasis in patients with, 35–6
 - three-step assessment case study, 6–8
 - vascular abnormalities with, 36
- repetitive limb spasms, clinical assessment, 23
- sarcoidosis. *See* neurosarcoidosis
- secondary progressive multiple sclerosis (SPMS)
 - avascular hip necrosis and fracture, 37–9
 - clinical course assessment, 15–16, 18–19
 - lower extremity weakness and neck flexion with, 27–8
 - misdiagnosis of, 19–21
 - pseudo exacerbations, 18–19
 - therapeutic management, 33–4
- sensorineural deafness, three-step assessment, 12–13
- sensory level indicators, MS diagnosis, 2–3
- sensory loss
 - case study involving, 6–8
 - feet and hands, numbness in, 9–11
 - “glove” and “stocking” distribution, 10
 - MS diagnosis, 2–3
 - peripheral nerve disease, 11–12
- sensory myelopathy, MS differential diagnosis, 1–4
- serological testing, MS diagnosis, 5–6
- Sjögren syndrome, 68–9
- smoking
 - cognitive impairment with MS and, 50
 - treatment-resistant MS and, 30–1
- somatosensory evoked potentials (SSEP), MS diagnosis, 5–6
- sphincteric dysfunction, as clinical feature of MS, 1–4
- sphingosine 1-phosphate (SIP) receptors, therapeutic management of MS and, 33
- spinal cord disease
 - arteriovenous malformation, 87–8
 - diagnostic challenges in, 79–88
 - herniation, 86–7
 - primary progressive multiple sclerosis, 80
 - static cervical myelopathy, 79–80
- spondylotic myelopathy, gait impairment, 82–3
- stellate maculopathy, 46
- “stocking” distribution of sensory loss, 10
- sudden hearing loss, MS differential diagnosis, 12–13
- superficial siderosis, anticoagulation therapy, 72
- T1-weighted imaging
 - clinically isolated syndrome, 15–16
 - investigational evidence, MS diagnosis, 4–6
- T2-weighted imaging
 - abnormal brain scan, 12–13
 - autosomal-dominant leukodystrophy, 61–2
 - benign relapsing remitting multiple sclerosis, 17
 - CADASIL, 56–7
 - clinically isolated syndrome, 15–16
 - CLIPPERS syndrome, 74–5
 - cognitive impairment with MS and, 50
 - gait impairment, clinical course assessment, 19–21
 - investigational evidence, MS diagnosis, 4–6
 - MS diagnosis, 6–8
 - secondary progressive multiple sclerosis, 18–19
 - therapeutic assessment, 30
- tachycardia, therapeutic management of MS and, 33
- therapeutic management of MS
 - glatiramer acetate intolerance, 31–3
 - injection intolerance and bradycardia, 33
 - interferon therapy, 33–4
 - natalizumab administration, 33–4
 - pregnant patients, 35
 - treatment-resistant MS and tobacco use, 30–1
 - vascular abnormalities in patients and, 36
- thoracic myelopathy
 - ischemic, 83–4
 - postvaccinal inflammatory, 84–5
- three-step diagnostic procedure
 - benign relapsing remitting multiple sclerosis, 17
 - case studies using, 6–14
 - classical clinical features identification, 1–4
 - investigational evidence assessment, 4–6
 - migraine differential diagnosis, 8–9
 - neurological examination, 3–4
 - overview, 1–6
 - radiologically isolated syndrome, 16
 - relapsing remitting multiple sclerosis case study, 6–8
- Tinel’s sign, 11–12
- tobacco use. *See* smoking
- tonic spasms
 - central nervous system (CNS) demyelination, 23
 - as clinical feature of MS, 1–4
- transverse myelitis, differential diagnosis, 82–4
- treatment-resistant MS, tobacco use and, 30–1
- tremor, progressive, in MS, 64
- trigeminal neuralgia, 1–4
 - as heralding MS symptom, 24–5
- Uhthoff phenomenon, MS with
 - chest abnormality with optic nerve edema, 47–8
 - clinical features, 28–9
 - internuclear ophthalmoplegia, 40
- uncommon MS clinical presentations, 23–9
 - repetitive limb spasms, 23
- upper limb incoordination, relapsing remitting MS, 71–2
- upper motor neuron impairment
 - lower extremity pain and, 37–9
 - MS diagnosis, 3–4
 - pyramidal distribution, 18–19
- vascular abnormalities, in MS patients, 36
- vasculitis, sympathicomimetic drug reaction, 60
- vertigo
 - Alzheimers disease with MS and, 50–2
 - clinically isolated syndrome, 21–2
- visual evoked potentials (VEP), MS diagnosis, 5–6
- visual impairment
 - demyelinating ocular disease, 40–8
 - fluctuating, then progressive course, 28–9

Index

MS diagnosis, 6–8	non-MS diagnoses, 41	autosomal-dominant
optic neuritis and, 1–4	recurrent optic nerve edema, 46	leukodystrophy, 61–2
visual loss	vomiting, neuromyelitis optica	gliomatosis cerebri, 52–4
bilateral loss, 43–4	spectrum disorder, 75–6	malignant hypertension, 44–5
chest abnormality and optic nerve		neuromyelitis optica spectrum
edema, 47–8	white matter lesions	disease, 43–4
Leber’s heredity optic neuropathy,	Alexander disease, 72–3	
48	alien limb phenomenon and, 54–6	Zamboni, 36